CN1158095C - Chinese medicine for treating rheumatoid arthritis - Google Patents

Chinese medicine for treating rheumatoid arthritis Download PDF

Info

Publication number
CN1158095C
CN1158095C CNB011397799A CN01139779A CN1158095C CN 1158095 C CN1158095 C CN 1158095C CN B011397799 A CNB011397799 A CN B011397799A CN 01139779 A CN01139779 A CN 01139779A CN 1158095 C CN1158095 C CN 1158095C
Authority
CN
China
Prior art keywords
radix
root
present
chinese medicine
rheumatoid arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB011397799A
Other languages
Chinese (zh)
Other versions
CN1356135A (en
Inventor
阎纯义
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB011397799A priority Critical patent/CN1158095C/en
Publication of CN1356135A publication Critical patent/CN1356135A/en
Application granted granted Critical
Publication of CN1158095C publication Critical patent/CN1158095C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a preparation of a Chinese medicine for treating rheumatoid arthritis, which is prepared from common monkshood mother root, prepared common monkshood daughter root, ephedra, Chinese clematis, long-noded pit viper, earthworm, centipede, incised notoptetygium rhizome, doubleteeth pubesscent angelica root, ledebouriella root, hemlock parsley, milkvetch root, angelica and liquorice as raw materials. The present invention is made by the processing process of the traditional Chinese medicine. The present invention is made of pure Chinese herbal medicine, with the well combination of tonification and conducing circulation. The present invention can promote vital qi in an organism, enhance the capacity of exogenous pathogenic factor resistance and treat both manifestation and root cause of diseases, with small side effect, appropriate matching and conspicuous curative effect. Clinical symptoms disappear rapidly by the use of the present invention without rebound phenomena after people are cured.

Description

The Chinese medicine preparation of treatment rheumatoid arthritis
Technical field:
The present invention discloses a kind of Chinese medicine preparation for the treatment of rheumatoid arthritis, relates to the medicine of rheumatism, rheumatoid disease, belongs to the Chinese medicine and pharmacy technical field.
Background technology:
Rheumatoid arthritis belongs to the traditional Chinese medical science " arthromyodynia " category.Be the commonly encountered diseases and the frequently-occurring disease of northern area, its cause of disease is battalion's deficiency of defensive qi, and space between skin and muscles is not solid, and the damp of having a cold again causes due to the passages through which vital energy circulates QI and blood impatency.Relevant treatment by Chinese herbs medicine is as " controlling numbness looses ", " indometacin " etc., and how with meridians dredging, expelling wind and removing dampness is main, though can obtain some effects, but easily recur after all existing drug withdrawal to some extent, grow and can lead to complications the course of treatment, and have than serious adverse.Treat often thoroughly inadequately, the state of an illness twines stupid, Jing Jiu Bu More, and very easily recurrence makes pathogen go deep into muscles and bones, and coagulation of QI-blood is not all right, becomes that to give birth to the phlegm-damp stasis of blood turbid, and the meridians obturation is obstructed.
Summary of the invention:
The present invention discloses a kind of Chinese medicine preparation for the treatment of rheumatoid arthritis, is pure Chinese medicinal preparation, has strengthening vital QI to eliminate pathogenic factors, and the effect of the eliminating impediment that dispels the wind is cured the no rebound phenomena in back.
Technical solution of the present invention is as follows: according to pathogeny and the Therapeutic Principle of Chinese medicine to rheumatoid arthritis, with reference to the modern medicine achievement, in the medical treasure-house of motherland, choose and have liver-kidney tonifying, nourishing blood and replenishing essence, wind-expelling and dispelling dampness, activating blood circulation to dissipate blood stasis, the pure Chinese herb medicine of anti-inflammatory analgetic is made Chinese medicine preparation through science, makes every effort to cause by the internal balance machine of body, transfer the interior healthy energy of body and resist exopathogen, fundamentally reach therapeutic purposes.
The present invention is the Chinese medicine preparation of being made by weight by following medicine:
Radix Aconiti 1.0~1.5, Radix Aconiti Lateralis Preparata 1.0~1.2, Herba Ephedrae 2.0~2.5, Radix Clematidis 2.0~2.5, Agkistrodon 1.0~1.5, Pheretima 2.0~2.5, Scolopendra 2.0~3.0, Rhizoma Et Radix Notopterygii 2.0~2.5, Radix Angelicae Pubescentis 2.0~2.5, Radix Saposhnikoviae 1.5~2.0, Rhizoma Chuanxiong 1.5~2.0, the Radix Astragali 5~7.5, Radix Angelicae Sinensis 2.0~2.5, Radix Glycyrrhizae 0.5~075.
Preferred weight portion rate of the present invention is:
Radix Aconiti 1, Radix Aconiti Lateralis Preparata 1, Herba Ephedrae 2, Radix Clematidis 2, Agkistrodon 1, Pheretima 2, Scolopendra 2, Radix Angelicae Pubescentis 2, Rhizoma Et Radix Notopterygii 2, Radix Saposhnikoviae 1.5, Rhizoma Chuanxiong 1.5, the Radix Astragali 5, Radix Angelicae Sinensis 2, Radix Glycyrrhizae 0.5.
Processing procedure:
Take by weighing said medicine by weight, it is stand-by that Radix Aconiti Lateralis Preparata, Herba Ephedrae, Radix Clematidis, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Radix Saposhnikoviae, Rhizoma Chuanxiong, the Radix Astragali, Radix Angelicae Sinensis, Radix Glycyrrhizae powder are broken into 80~120 order fine powders, again with Radix Aconiti, Agkistrodon, Scolopendra, Pheretima decocting three times, adding water respectively is 8,6,6 times of amounts, decocts filter and remove residue 2,1,1 hours, merge three times decocting liquid, be condensed into extractum,, make powdery powder with above-mentioned medicated powder mixing and stirring.
The present invention is to use Radix Aconiti, Radix Aconiti Lateralis Preparata, Herba Ephedrae, the Radix Clematidis dispelling cold by warming the meridian is a monarch drug, with Agkistrodon, Pheretima, the product of Scolopendra insects, the function benefaction is walked to scurry, search wind and pick network, detoxicating and resolving stagnation of pathogens, remove stiff analgesia and be minister, be aided with two and live each, Radix Saposhnikoviae, Rhizoma Chuanxiong, the Radix Astragali, the Radix Angelicae Sinensis benefiting QI for activating blood circulation, dispelling pathogenic wind and eliminating phlegm, dredge the meridian passage and sharp joint, shared with Radix Saposhnikoviae and Radix Angelicae Sinensis, more increase the power of its cold relieving, the pain relieving to help the meridian dredging, Rhizoma Chuanxiong are the diffusing product of fragrance row, the energy promoting the circulation of QI to relieve pain, the effect that sensible QI and blood is arranged for the gas medicine in the blood, the Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription is for making, and all medicines share then has benefiting vital QI and blood, nourishing the liver and kidney, dispelling cold by warming the meridian, dispelling pathogenic wind and eliminating phlegm, the collateral dredging dehumidifying, detoxicating and resolving stagnation of pathogens, remove the effect of stiff pain relieving.
This patent is applicable to Liver and kidney two void, Qi and blood deficiency, the arthromyodynia of cold-damp resistance network.
Usage and consumption: oral.Formulation rate of the present invention can be according to variations such as route of administration, patient age, body weight, disease type and the orders of severity, and daily dose is 0.01~20mg/kg.Each 4~6g, secondary took with eliminating cold for resuscitation water or yellow wine and to take after mixing it with water every day.
Attention: be not taken by pregnant women the careful usefulness of hyperpietic.
Characteristics of the present invention are: pure Chinese herbal medicine is made, toxic and side effects is little, treating both the principal and secondary aspects of a disease, evident in efficacy, clinical symptom disappearance is rapid, cure the no rebound phenomena in back, be adapted to the treatment of rheumatism, rheumatoid arthritis, cervical spondylosis, scapulohumeral periarthritis, prolapse of lumbar intervertebral disc, sciatica, hyperosteogeny diseases.
For showing the therapeutic effect of medicine of the present invention, through the clinical observation of 40 routine systems: male's 23 examples, women's 17 examples, wherein, 31~40 years old 3 example, 41~51 years old 14 example, 51~60 years old 15 example, 6 examples more than 61 years old, the elder of the state of an illness 15 years, the shortest person 2 years.
One, diagnostic criteria: the standard (ARA) that U.S.'s rheumatism meeting 1987 is formulated is: limit stiff time>1 in morning hour, arthroncus>3 month, erythrocyte sedimentation rate>300mm/h, anti-" O ">800u, rheumatoid factor (RF) "+", rheumatoid subcutaneous nodule, the relative abnormal change of X ray examination; 4 persons are arranged in last 7, meet the diagnostic criteria of Chinese Medical Association's rheumatism association formulation for the second time.Picture of the tongue, pulse condition, symptom meet contained Liver and kidney two void in " the clinical research guideline of new Chinese medicine treatment numbness disease ", the tcm diagnosis standard of the arthromyodynia of cold-damp resistance network.
Two, include standard in: in all meeting, Western medicine diagnose and Chinese medical discrimination standard person, can include case in.
Three, get rid of case:, must stop using though 1 take Western medicine or other medicines person for during the primary disease; 2, late deformity, deformity, disability person get rid of; 3, gestation or women breast-feeding their children are to this medicine allergy sufferers under-18s or over-65s person the age; 4, merge cardiovascular, serious primary disease such as Liver and kidney and hemopoietic system, psychotic; 5, do not meet the standard of including in, not medication in accordance with regulations can't be judged curative effect or data not umbra sound curative effect or safety judgement person.
Four, observational technique: MethodsThe cases enrolled requires to fill in symptom, and sign is also done inspection items such as routine blood test, routine urinalysis, electrocardiogram, liver function, erythrocyte sedimentation rate, anti-" O ", the rheumatism factor, X-ray film, and wherein, clinical symptoms is filled in by the integration of Syndrome in TCM:
Initiatively said the symptom meter 4 minutes (+++).The symptom of getting is by remarkable or lasting appearance 3 minutes (++) respectively, and 2 minutes (+), 1 minute (-), asymptomatic meter 0 minute, tongue fur pulse condition wherein 1 positive shape person were counted 6 fens, and auxiliary examination project and sign are filled in by domestic current one measurement unit.
Five, medication: each 5 grams, every day 3 times, oral, boiled water send down, and yellow wine is for drawing, and 28 days is a course of treatment, and be an observation period 3 courses of treatment.Finish the back comprehensive review course of treatment, adopt the method for treatment front and back own control, it is carried out statistical procedures, other related drugs of stopping using during the treatment.
Six, curative effect determinate standard:
1, cure: symptom and sign all disappear, and it is normal that functional activity recovers, and lab testing and X ray examination all recover normal.
2, produce effects: symptomatology is eliminated or cardinal symptom is eliminated, and function of joint is recovered substantially, can participate in operate as normal and work, and lab testing and X ray examination have remarkable improvement.
3, effective: symptom and sign take a turn for the better, and main function of joint is recovered substantially or had made marked progress, and lab testing and X ray examination take a turn for the better.
4, invalid: relatively preceding with treatment, each side does not all have progress.
Seven, observe conclusion:
The doing well,improving information slip
Symptom The example number Before the treatment After the treatment V-value The P value
+++ ++ + - +++ ++ + -
Muscular soreness 40 8 20 10 2 0 3 13 24 6.12 <0.05
Arthroncus 40 12 22 6 0 0 2 19 19 7.08 <0.05
Aversion to cold and preference for warmth 40 11 19 8 2 0 0 20 20 6.61 <0.05
Hands and feet being not warm 40 5 17 12 6 0 2 16 22 4.95 <0.05
Amyotrophy 40 5 18 11 6 0 0 17 23 5.43 <0.05
Joint deformity 40 1 1 9 29 0 0 3 37 2.37 <0.05
Spontaneous sweating 40 1 5 11 23 0 1 8 31 2.08 <0.05
The waist knee joint is thin soft 40 0 3 10 26 0 0 2 38 3.36 <0.05
Local pyrexia 40 0 8 14 18 0 1 3 36 4.25 <0.05
Joint stuffiness 40 3 8 15 14 0 4 9 17 3.00 <0.05
Function of joint 40 0 10 14 16 0 2 1 26 4.07 <0.05
Numb weight person 40 1 14 14 15 0 0 9 36 2.72 <0.05
Influence to erythrocyte sedimentation rate, anti-O:
Project Number Before the treatment After the treatment V-value The P value
Erythrocyte sedimentation rate 40 72.4±2.36 32.7±1.56 8.72 <0.01
Anti-O 40 8.08±24.7 3.46±17.6 10.72 <0.01
Curative effect to the lonizing radiation rheumatoid factor:
Project Before the treatment After the treatment V-value The P value
Negative Positive Negative Positive
Rheumatoid factor 21 19 36 4 9.12 <0.01
Optical test 26 14 31 9 2.07 <0.01
Influence to the tongue arteries and veins:
Deep-thready pulse Stringy and tense pulse Moderate pulse and Light red tongue Light red tongue V-value The P value
Before the treatment 18 20 2 35 5 9.93 <0.01
After the treatment 13 14 13 32 8 0.82 >0.05
Influence to RBC, HB:
Project Number Before the treatment After the treatment V-value The p value
RBC 40 4.10±0.50 4.20±0.50 1.69 >0.05
HB 40 11.40±18.80 1119.4±16.6 1.08 >0.05
By to 40 routine clinical observations, clinical cure 14 examples account for 35%, produce effects 14 examples, account for 35%, effective 10 examples account for 25%, invalid 2 examples, total effective rate 95%, routine blood test and hepatic and renal function often change undoubtedly before and after the medication, show that this medicine does not have hepatorenal damage, and can improve muscle joint swelling and pain symptom effectively, slow down erythrocyte sedimentation rate and reduce anti-" O ", total effective rate reaches 95%.
The specific embodiment:
Further specify the present invention below in conjunction with embodiment:
Embodiment:
Take by weighing Radix Aconiti Lateralis Preparata 1kg, Herba Ephedrae 2kg, Radix Clematidis 2kg, Rhizoma Et Radix Notopterygii 2kg, Radix Angelicae Pubescentis 2kg, Radix Saposhnikoviae 1.5kg, Rhizoma Chuanxiong 1.5kg, Radix Astragali 5kg, that Radix Angelicae Sinensis 2kg, Radix Glycyrrhizae 0.5kg are ground into 120 order fine powders is stand-by, again with Radix Aconiti 1kg, Agkistrodon 1kg, Pheretima 2kg, Scolopendra 2kg decocting three times, adding water respectively is 8,6,6 times of amounts, decocted 2,1,1 hours, filter and remove residue merges three times decocting liquid, is condensed into extractum, with above-mentioned medicated powder mixing and stirring, make powdery powder.

Claims (2)

1, a kind of Chinese medicine preparation for the treatment of rheumatoid arthritis is characterized in that being made by following parts by weight proportion raw material:
Radix Aconiti 1.0~1.5, Radix Aconiti Lateralis Preparata 1.0~1.2, Herba Ephedrae 2.0~2.5, Radix Clematidis 2.0~2.5,
Agkistrodon 1.0~1.5, Pheretima 2.0~2.5, Scolopendra 2.0~3.0, Rhizoma Et Radix Notopterygii 2.0~2.5,
Radix Angelicae Pubescentis 2.0~2.5, Radix Saposhnikoviae 1.5~2.0, Rhizoma Chuanxiong 1.5~2.0, the Radix Astragali 5~7.5, Radix Angelicae Sinensis 2.0~2.5,
Radix Glycyrrhizae 0.5~0.75.
2, Chinese medicine preparation according to claim 1 is characterized in that being made by following parts by weight proportion raw material:
Radix Aconiti 1, Radix Aconiti Lateralis Preparata 1, Herba Ephedrae 2, Radix Clematidis 2, Agkistrodon 1, Pheretima 2, Scolopendra 2, Rhizoma Et Radix Notopterygii 2, Radix Angelicae Pubescentis 2, Radix Saposhnikoviae 1.5, Rhizoma Chuanxiong 1.5, the Radix Astragali 5, Radix Angelicae Sinensis 2, Radix Glycyrrhizae 0.5.
CNB011397799A 2001-12-03 2001-12-03 Chinese medicine for treating rheumatoid arthritis Expired - Fee Related CN1158095C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB011397799A CN1158095C (en) 2001-12-03 2001-12-03 Chinese medicine for treating rheumatoid arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB011397799A CN1158095C (en) 2001-12-03 2001-12-03 Chinese medicine for treating rheumatoid arthritis

Publications (2)

Publication Number Publication Date
CN1356135A CN1356135A (en) 2002-07-03
CN1158095C true CN1158095C (en) 2004-07-21

Family

ID=4675406

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB011397799A Expired - Fee Related CN1158095C (en) 2001-12-03 2001-12-03 Chinese medicine for treating rheumatoid arthritis

Country Status (1)

Country Link
CN (1) CN1158095C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103432418B (en) * 2013-09-06 2015-10-28 大连民族学院 Chinese medicine composition of a kind of gout pain relieving and its production and use

Also Published As

Publication number Publication date
CN1356135A (en) 2002-07-03

Similar Documents

Publication Publication Date Title
CN104383055A (en) Drug for treating end-stage liver diseases caused by chronic hepatitis B and preparation method of drug
CN103127422B (en) Medicament for treating ulcerative colitis
CN1046421C (en) Drug for curing pulmonary tuberculosis
CN1389255A (en) Composite Chinese medicine for treating rheumarthritis and rheumatoid arthritis
CN102579720A (en) Medicament for treating facial paralysis and preparation method thereof
CN1158095C (en) Chinese medicine for treating rheumatoid arthritis
CN100344318C (en) Medicine for treating apoplectic sequel and prepn. thereof
CN108578603B (en) Traditional Chinese medicine compound for treating kidney deficiency and marrow depletion type knee osteoarthritis based on shaoyang bone governing theory and application thereof
CN102600251B (en) Rheumatism-rehabilitating traditional Chinese formulation
CN101062340B (en) Chinese traditional medicine composition for liver revovery
CN114588242B (en) Pharmaceutical composition for treating rheumatoid arthritis
CN1294961C (en) Oral liquid for curing myocardial ischemia and process for preparing the same
CN103349767B (en) Inula nervosa Wall oil capsule preparation and preparation method thereof
CN1054769C (en) Chinese medicinal preparation for treatment of psoriasis and preparation method thereof
CN115814040B (en) Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation thereof
CN114272329B (en) Traditional Chinese medicine composition for treating liver and kidney deficiency type cervical spondylosis, preparation and application
CN114377062B (en) Traditional Chinese medicine composition for treating liver and kidney deficiency type bone arthralgia, preparation and application
CN103316133B (en) Medicine for treating lame impediment
CN1176679C (en) Chinese medicine for treating rheumatism and rheumatoid diseases
CN102836346B (en) Traditional Chinese medicine for treating lumbar disc herniation
CN100346813C (en) Medicine for treating coronary heart disease
CN1238013C (en) Myocarditis treating Chinese medicine prepn
CN1056998C (en) A Chinese medicinal pill for treating bone tuberculosis and its preparation method
CN1113667C (en) Medicine for treating rheumatic and rheumatoid diseases
CN101269131B (en) Traditional Chinese medicine for treating rheumatism paralysis

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee